View:
Download DOC
Download PDF
Download XLS
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-38475
Issuer: ASLAN Pharmaceuticals Ltd
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: Temasek Avenue, Level 18
Centennial Tower
Singapore SINGAPORE 03190
Telephone number: 65 6222 4235
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
American Depositary Shares
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2024-09-06 By Aravind Menon Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. 
Delisting Determination, The Nasdaq Stock Market, LLC, September 6, 2024.
ASLAN Pharmaceuticals Limited.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of ASLAN Pharmaceuticals Limited, effective
at the opening of the trading session on September 16, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rules 5550(a)(2) and 5550(b)(1).
The Company was notified of the Staff determination on July 9, 2024.
The Company did not appeal the Staff determination to the Hearings
Panel. The Company securities were suspended on July 19, 2024.
The Staff determination to delist the Company securities became
final on July 19, 2024.